Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.

14 Mar 2013

Cognitive behavioral therapy brings relief to people with diabetic neuropathies, researchers find

Researchers at Boston University School of Medicine and VA Boston Healthcare System have found that cognitive behavioral therapy can help relieve pain for people with painful diabetic neuropathies.

5 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

DBS can lead to long-term improvement in patients with neuropathic pain

For many patients with difficult-to-treat neuropathic pain, deep brain stimulation (DBS) can lead to long-term improvement in pain scores and other outcomes, according to a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

14 Feb 2013

Study finds reason why patients with chronic pain often suffer from impaired short -term memory

A group of Portuguese researchers from IBMC and FMUP at the University of Porto has found the reason why patients with chronic pain often suffer from impaired short -term memory.

9 Feb 2013

Regular exercise reduces development of painful diabetic neuropathy in animals

Regular exercise reduces the development of painful diabetic neuropathy in animals—apparently related to increased expression of a protective substance called "heat shock protein" 72 (Hsp72), reports an experimental study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

5 Feb 2013

Neurolysis combats hip replacement sciatic nerve pain

Preliminary research suggests that neurolysis can significantly reduce neuropathic pain in patients who develop sciatic nerve palsy after total hip replacement.

14 Jan 2013

Electroconvulsive therapy releases opiate-like substances

Researchers used electricity on certain regions in the brain of a patient with chronic, severe facial pain to release an opiate-like substance that's considered one of the body's most powerful painkillers.

3 Jan 2013

Parasympathetic dysfunction underpins Gulf War Syndrome

Gulf War veterans with self-reported symptoms of autonomic dysfunction have objective evidence of underlying damage to central and peripheral cholinergic function, a study shows.

4 Dec 2012

EC grants CE mark to InSightec’s ExAblate Neuro ultrasound system

InSightec Ltd. announced that its transcranial focused ultrasound system, ExAblate Neuro, has been awarded the European CE mark for the treatment of neurological disorders in the brain including essential tremor, Parkinson's disease and neuropathic pain.

4 Dec 2012

InSightec receives European CE mark for ExAblate Neuro system

Elbit Imaging Ltd. announced today that on December 3, 2012, Elbit Medical Technologies Ltd., announced that InSightec Ltd. has been awarded the European CE mark for its transcranial focused ultrasound system, ExAblate Neuro, with respect to the treatment of neurological disorders in the brain, including essential tremor, Parkinson's disease and neuropathic pain.

4 Dec 2012

Spaniels' neuropathic pain condition stays static without surgery

Cavalier King Charles with neuropathic pain induced by a condition characterized by a brain–skull size mismatch do not show significant improvement after nonsurgical treatment for the condition, indicate UK study results.

20 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Musculoskeletal ultrasound being increasingly used for diagnosis and management of rheumatic diseases

More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.

29 Oct 2012

Companionship can reduce nerve-related pain

Companionship has the potential to reduce pain linked to nerve damage, according to a new study.

16 Oct 2012

Anesthetic-loaded liposomes can delay onset of neuropathic pain

Using tiny spheres filled with an anesthetic derived from a shellfish toxin, researchers at Boston Children's Hospital and the Massachusetts Institute of Technology have developed a way to delay the rise of neuropathic pain, a chronic form of pain that arises from flawed signals transmitted by damaged nerves.

10 Oct 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Predictors for pain after breast cancer surgery unveiled

Researchers have identified that chronic preoperative pain, axillary surgery, and psychologic robustness significantly predict acute pain outcomes after breast cancer surgery.

5 Sep 2012